Preterm Birth Prevention and Management Market – By Therapy Type, By Route of Administration, By Distribution Channel, Global Forecast, 2025 to 2034

Preterm Birth Prevention and Management Market Size

The global preterm birth prevention and management market was valued at USD 1.8 billion in 2024 and is expected to exhibit growth at a CAGR of 7.7% from 2025 to 2034 period, owing to the growing number of pre-term births, technological innovations, increased rates of maternal risk factors, and growing emphasis on neonatal care that are interconnected.
 

Preterm births are one of the leading causes of neonatal morbidity and mortality across the globe. For instance, according to the World Health Organization (WHO), 15 million babies on average are born preterm every year and this number is constantly increasing. In addition, it was reported that being born preterm accounts for around 1 million deaths of children under the age of 5, in the year 2022. As more women give birth prematurely, a growing need for preventative and managerial measures has bolstered growth of the market.
 

Furthermore, advances in technology for prenatal care, such as new diagnostic equipment, preventative monitoring, and other treatment options, have improved the management of women with high-risk pregnancies and the outcomes of preterm infants.
 

Intervention preterm birth is defined as the period of medical attention before and during the tenuous phase of pregnancy for infants to prevent morbidity and mortality through strategic medical tactics like using progesterone, tocolytic medications, amniocentesis, and magnesium sulfate to prolong infants' lives in the womb.
 

Preterm Birth Prevention and Management Market Trends

• The market dealing with preterm birth intervention and management is undergoing some changes that are going to affect its growth and expansion. Some of the catalytic factors such as increasing adoption of digital health tools, advancement in personalized medicine, and greater investment in drug therapy R&D are contributing toward the growth of the industry.
   
• Additionally, there is an increasing tendency targeting the personalized prevention of preterm birth. Providers of healthcare services are increasingly deploying genetic screening, biomarkers as well as risk profiling to design one of the most effective treatment plans for pregnant women, which makes the prevention and management more efficient and effective with such a growing trend.
   
• Furthermore, the employment of artificial intelligence in medicine and the usage of machine learning in preterm birth prevention and management is trending upward. The patient files of a woman expecting a baby with everything ranging from her medical history, lifestyle choices, and prenatal screenings are put through an AI algorithm designed to detect the possibility of preterm birth. Such technologies are improving early risk detection and allowing healthcare professionals to give more precise treatment. These developments are expected to drive the growth of the market.
   

Preterm Birth Prevention and Management Market Analysis 

Based on therapy type, the market is segmented as progesterone therapy, corticosteroid therapy, tocolytic therapy, antibiotics therapy, heparin prophylaxis therapy, and other therapy types. The progesterone therapy segment is expected to drive business growth and expand at a CAGR of 8%, reaching over USD 1.5 billion by 2034.
 

• Controlled progesterone therapy is reported to be effective in reducing the chance of premature birth for women who have given birth prematurely previously or are determined to be at high risk. The verification of efficacious prevention of early labor in women with short cervices or multiple gestations serves as an added stimulus reason to the drivers of this therapy.
   
• Furthermore, there is an upward shift in the high-risk pregnancy population caused by issues like aging mothers, obesity, and multiple births, creating a higher need for strengthening solutions like progesterone therapy. This increase in at-risk pregnancies is what boosts the need for treatments with progesterone, hence solidifying the segment's expansion.
   

Based on route of administration, the preterm birth prevention and management market is segmented into parenteral, oral, and topical. The parenteral segment is expected to drive business growth and expand at a CAGR of 7.6%, reaching over USD 2.7 billion by 2034.
 

• The offering of progesterone or tocolytics becomes more effective when done through parenteral administration such as IV or IM. These treatments are critical in preventing preterm births, particularly for high-risk pregnant women. The parenteral route offers great benefit of controlled dosing. Additionally, it bypasses the digestive system making it a preferred method in clinical settings.
   
• Further, it also enables faster onset of action. This is particularly useful in moderating preterm labor intervention efforts. The ability to act fast is the number one selling point for treating the ailment which specific type of parenteral delivery is preferred by healthcare providers and consequently causes growth in this segment of the service market.

Based on distribution channel, the preterm birth prevention and management market is classified into brick and mortar and e-commerce. The brick and mortar segment dominated the market with a revenue share of 82.5% in 2024.
 

• Maternal-fetal health services like prenatal screening, therapy with progesterone, and management of high-risk preterm birth are critical and need the support of brick-and-mortar healthcare centers. This is true especially as more pregnant women, specifically high-risk individuals, are looking for ways to avoid these problems and infrastructure is improving, giving rise to more services for preterm birth management.
   
• Additionally, those facilities with obstetricians, neonatologists, and maternal-fetal medicine specialists provide services for high-risk obstetric patients in order to reduce pregnancy-associated morbidity. These services are crucial for diagnosis and management of conditions that cause preterm birth such as cervical incompetence or preeclampsia. The existence of these professionals in the brick-and-mortar facilities assists in addressing the issues related to preventing pre-term birth delivering strategies to the market to promote such institutions.

U.S. preterm birth prevention and management market accounted for USD 671.6 million in 2024 and is anticipated to grow at a CAGR of 7.2% between 2025 to 2034 period.
 

• The proportionality of premature births in U.S. is around 10%. which is more than any other developed nation. This indicates the dire necessity of precise and timely initiatives towards elimination and control strategies for such births. The existing problem of decreasing the number of preterm births requires more advanced methods, treatments, and diagnostic devices to be integrated into the American healthcare system, and so the need becomes even greater.
   
• Additionally, new technologies, therapies, and practices designed for the elimination and treatment of premature births are parallel with the breakthrough and innovation that is happening in maternal fetal medicine which the countries are undertaking. There are hope emerging for the establishment of preterm births elimination and treatment market in the U.S., thanks to the new genetic test technologies, new biomarkers, and pregnancy risk monitoring systems.
   

Germany preterm birth prevention and management market is projected to grow remarkably in the coming years.
 

• Germany boasts a good healthcare system together with a well established maternal and neonatal care services. There are modern hospitals and clinics, as well as separate centres for materno-fetal medicine, so there is a possibility for the primary prevention and management of prelabor difficulties such as prematurity in the country. In addition, the healthcare system of the country ensures that any pregnancy that is considered high risk gets appropriate attention and action taken to prevent predelivery problems, creating a market for early birth intervention.
   
• Furthermore, the nation is a leader in ultrasonography and obstetrical equipment marketing and development. The existence of diagnoses, ultrasounds, fetal monitors, and genetic tests allows doctors to identify the risks of preterm birth early and treat the pregnancy more comprehensively. These devices are of utmost importance in averting and controlling preterm births, thus fostering the growth of more such services and products in the country.
   

China holds a dominant position in the Asia Pacific preterm birth prevention and management market.
 

• The increasing prevalence of ART such as in-vitro fertilization (IVF) in China is translating to an increase in the number of preterm birth and high-risk births. Preterm labor is mostly induced among women who undergo fertility treatment making the management of preterm births such as progesterone therapy necessary.
   
• Moreover, with the advancement of maternal-fetal medicine in China, the recognition and targeting of causes for preterm births is on the rise. With the help of specialized ultrasound as well as genetic screenings, a number of women predisposed to preterm labor can be identified and managed early as well as prevent the measures from being adopted. This is propelling the growth of the market.
   

Preterm Birth Prevention and Management Market Share

The market has participants that range from pharmaceutical companies and medical device companies to healthcare service providers. The key players aim at more advanced development, such as progesterone therapies, tocolytics or other early diagnosis tools and even specialized maternal care have become crucial for management solution providers. The competition is at its peak as many companies are working to improve the outcomes of maternal and neonatal health through intensive research investments.
 

Preterm Birth Prevention and Management Market Companies

Prominent players operating in the preterm birth prevention and management industry include:

• AbbVie
• AMAG Pharmaceuticals
• Ferring Pharmaceutical
• Merck
• Obseva
• Pfizer
• Takeda Pharmaceutical
   

Preterm Birth Prevention and Management Industry News:

• In March 2021, Covis Group announced that 17-OHPC and vaginal progesterone significantly decrease the chances of early preterm births in vulnerable single pregnancies before the 34 weeks mark, based on the findings from the EPPPIC study. Additionally, this reinforces the company’s strategic competitive position for 17-OHPC, by both demonstrating its effectiveness and strengthening its usage for prevention of preterm births.
   

The preterm birth prevention and management market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy Type

• Progesterone therapy
• Corticosteroid therapy
• Tocolytic therapy
• Antibiotics therapy
• Heparin prophylaxis therapy
• Other therapy types

Market, By Route of Administration

• Parenteral
• Oral
• Topical

Market, By Distribution Channel

• Brick and mortar
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE